On November 9, 2016, Bob Thomas will be a Panelist at the Boston Bar Association’s Off-Label Prescription Drug Use: An Access Issue. There has long been a ban on off-label promotion of a particular drug; the Amarin and Caronia cases withstood challenges on First Amendment grounds, each of which has wide implications for the pharmaceutical industry, including increased off-label drug use and accompanying costs. This program will be divided into two panels and will provide an overview of the cases, laws and regulations relative to off-label prescription, including the legal and policy issues that create access obstacles.
5:00 P.M. – 7:00 P.M.
Boston Bar Association – 16 Beacon Street, Boston, MA
On July 28, 2016, Suzanne Durrell joined a distinguished panel that discussed the implications of the U.S. Supreme Court’s June Escobar Ruling on False Claims Act Cases—Perspectives from all sides of the issues. This panel was hosted by the Massachusetts Chapter of the Federal Bar Association. Joining Suzanne on this panel was the Honorable Dennis F. Saylor, IV, Assistant U.S. Attorney Gregg Shapiro, and Attorney Larry M. Kraus.
4:00 P.M. – 5:30 P.M.
On June 10, 2016, Bob Thomas participated in this year’s ABA Civil False Claims Act 2016: 11th National Institute on the Civil False Claims Act and Qui Tam Enforcement. His panel examined the Settlement of a False Claims Act (FCA) Healthcare Case.
The Park Hyatt
1201 24th Street, NW
Washington, DC 20037
June 8-10, 2016
On May 31, 2016, we helped celebrate the Boston Chapter’s ACLU Bill of Rights Dinner – an annual celebration of liberty and justice for all. Bob Thomas is a proud member of the Board of Directors.
Boston Marriott Copley Place
110 Huntington Avenue, Boston
Reception 5:30 | Dinner 6:30
On May 24, 2016, Suzanne Durrell spoke on Federal Developments at the Boston Bar Association’s Health Care Fraud 2016: Government and Defense Perspectives. The program examined federal and state enforcement efforts aimed at post-acute and long term care providers. It included an analysis of the government’s prosecution of Kindred Healthcare and its RehabCare subsidiaries and the defense and compliance implications for therapy services at long term care facilities, such as nursing homes.